Combined Effects of Programmed Cell Death-1 Blockade and Endostar on Brain Metastases of Lung Cancer

被引：3

作者：

Qi, Xuejiao ^{[1
]}

Zhao, Yinlong ^{[2
]}

Yang, Song ^{[3
]}

Sun, YuMeng ^{[3
]}

Liu, Honglei ^{[4
]}

Liu, Pengyu ^{[3
]}

Feng, Shiyao ^{[3
]}

Tui, Hongbo ^{[3
]}

Yuan, Zheng ^{[3
]}

Yang, Jiankai ^{[1
,3
]}

Bu, Hui ^{[1
]}

机构：

[1] Hebei Med Univ, Hosp 2, Dept Neurol, Shijiazhuang 050000, Hebei, Peoples R China

[2] Hebei Med Univ, Hosp 2, Dept Intens Care Unit, Shijiazhuang 050000, Hebei, Peoples R China

[3] Hebei Med Univ, Hosp 2, Dept Neurosurg, Shijiazhuang 050000, Hebei, Peoples R China

[4] Third Hosp Shijiazhuang, Dept Neurosurg, Shijiazhuang 050000, Hebei, Peoples R China

来源：

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 2023年 / 23卷 / 06期

关键词：

Lung cancer; brain metastasis; immune checkpoint; PD-1; endostar; tumor metastasis; ANGIOGENESIS; CHECKPOINTS; INHIBITION; MECHANISMS; THERAPY; NSCLC;

D O I：

10.2174/1871520622666220827125929

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The blockade of programmed cell death-1 (PD-1) and recombinant human endostatin can be used for the treatment of non-small cell lung cancer (NSCLC) and its metastasis. This study aims to explore the therapeutically potential of PD-1 blockade plus Endostar in brain metastasis of NSCLC. Methods: The mouse brain metastases model was established using Lewis lung carcinoma luciferase (LLC-Luc) and PC-9-Luc cells. Tumor metastasis in the brain and tumor burden were analyzed by using bioluminescence imaging (BLI), qRT-PCR and ELISA which were used to determine the mRNA and protein levels of biomarkers in tumor tissues. Immunohistochemical staining was used to determine the expression and location of CD31 in tumor tissues in the brain. Results: Treatment with anti-PD-1 and Endostar suppressed tumor metastasis in the brain and prolonged overall survival rate in LLC-Luc and PC-9-Luc brain metastases mouse model. In addition, treatment with anti-PD-1 and Endostar inhibited the expressions of CD31 and VEGF in tumor tissues in the brain. Furthermore, treatment with anti-PD-1 and Endostar significantly suppressed the levels of IL1 beta, IFN gamma, and TGF beta in the tumor tissues. Conclusion: The combination of PD-1 blockade and endostar suppressed brain metastases of NSCLC.

引用

页码：709 / 716

页数：8

共 33 条

[31] Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects [J].

Zhao, Xiaoliang ;

Su, Yanjun ;

You, Jian ;

Gong, Liqun ;

Zhang, Zhenfa ;

Wang, Meng ;

Zhao, Zhenqing ;

Zhang, Zhen ;

Li, Xiaolin ;

Wang, Changli .

ONCOTARGET, 2016, 7 (38) :62619-62626

[32] Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer: a pilot study [J].

Zhou Jian-feng ;

Bai Chun-mei ;

Wang Yu-zhou ;

Li Xiao-yuan ;

Cheng Yue-juan ;

Chen Shu-chang .

CHINESE MEDICAL JOURNAL, 2011, 124 (24) :4299-4303

[33] Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges [J].

Zhou, Shujie ;

Xie, Jingjing ;

Huang, Zhaoqin ;

Deng, Liufu ;

Wu, Leilei ;

Yu, Jinming ;

Meng, Xiangjiao .

CANCER LETTERS, 2021, 502 :166-179

← 1 2 3 4 →